Candida albicans (C.albicans) is the most common opportunistic human fungal pathogen causing invasive candidiasis, which is one of factors resulting in increasing morbidity and mortality in immunocompromised patients. Currently, limited types of antifungal drugs for clinical application, increased drug resistance, and slow progress of new drug development lead to more and more challenges in clinical treatment. Recently developed proteomics can provide a novel effective technology platform and has been applied to the study of C.albicans, including pathogenic factors, resistance mechanism, immune response, action mechanism of antifungal drugs, etc. In this paper, new development of proteomic technology and its application to the study on C.albicans were reviewed.